PET/CT zur Diagnostik des Prostatakarzinomes

N. M. Blumstein; S. N. Reske

doi:10.1055/s-2004-832457

Der Nuklearmediziner, Inhaltsverzeichnis

Der Nuklearmediziner 2004; 27(4): 304-314
DOI: 10.1055/s-2004-832457

PET/CT zur Diagnostik des Prostatakarzinomes

PET/CT in Detecting Prostate CancerN. M. Blumstein¹ , S. N. Reske¹

¹Abteilung Nuklearmedizin, Universitätsklinikum Ulm

Abstract

Zusammenfassung

Die Fusionsbildgebung der PET und der CT in einem Kombinationsgerät hat wegen ihrer vielseitigen PET-basierten Detektionsprinzipien mit anatomisch hochauflösender und präziser CT-basierter morphologischer Bildgebung ein hohes klinisches und wissenschaftliches Potenzial. Dieser Beitrag soll einen Ausblick über die Einsatzmöglichkeiten der PET/CT-Bildgebung im Staging und Restaging bei Patienten mit Prostatakarzinom vor dem Hintergrund des komplexen Krankheitsbildes und den derzeitigen Behandlungsrichtlinien darlegen.

Abstract

Acquisition of PET and CT images in a combined scanner allow accurate PET based metabolic imaging in a combination with high resolution and anatomical precise CT-based morphologic imaging. The short review summarises clinical indications and the potential of ¹¹C-cholin PET/CT in detecting prostate cancer.

Schlüsselwörter

PET/CT - Onkologie - Prostatakarzinome

Key words

PET/CT - oncology - prostate cancer

Volltext

Referenzen

Literatur

1 Grönberg H. Prostate cancer epidemiology. Lancet. 2003; 631 859-864
2 Koch K. PSA-Test und Karzinom - Ein Beispiel für das Dilemma der Früherkennung. Deutsches Ärzteblatt. 2003; 100 2486-2488
3 Robert Koch Institut .Krebs in Deutschland. online 21.3.2003
4 Rifkin M D. Prostate Cancer: The diagnostic dilemma and the place of imaging in detection and staging. World J Urol. 1998; 16 76-80
5 Dhom G. Prostata. In: Dörr W, Seiffert G (Hrsg). Pathologie des männlichen Genitale. Springer, Berlin, Heidelberg 1991; 455-642
6 Pienta K J, Esper P S. Risk factors for prostate cancer. Ann Intern Med. 1993; 118 793-803
7 Sanchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study. Prostate. 2003; 54 238-247
8 Golz R, Störkel S. Pathologische Anatomie maligner Tumoren der Prostata. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 13
9 Bostwick D G. Staging prostate cancer - 1997: current methods and limitations. Eur Urol. 1997; 32 (Suppl 3) 2-14
10 Helpap B. Prognostic factors of prostatic carcinoma. Pathologe. 1998; 19 42-52
11 Voges G E. Das klinisch organbegrenzte, radikal operierte Adenokarzinom der Prostata. Habilitationsschrift. Johann Gutenberg-Universität, Mainz 1992
12 McNeal J E. Normal and pathologic anatomy of prostate. Urology. 1981; 17 (Suppl 3) 11-16
13 Bostwick D G, Cooner W H, Denis L, Jones G W, Scardino P T, Murphy G P. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992; 70 (Suppl 1) 291-301
14 Wittekind C, Meyer H J, Bootz F. TNM-Klassifikation maligner Tumore. 6. Aufl., Springer, Berlin, Heidelberg 2003
15 de la Monte S M, Moore G W, Hutchins G M. Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment. Cancer. 1986; 58 985-993
16 Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer. 1984; 54 3078-3084
17 Kastendieck H, Bressel M, Henke A, Husselmann H. The incidence of regional lymph node metastases in operable prostatic carcinoma. Dtsch Med Wochenschr. 1980; 105 1348-1354
18 Wirth S, Froschermaier S, Manseck A. Die Rolle des PSA in der Diagnostik und des Prostatakarzinoms. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 106
19 www.awmf-Leitlinien.de
20 Schroeder F. The European randomized study of screening for prostate cancer (ERSPC). Br J Urol. 1997; 79 68-71
21 www.eua.org
22 Catalona W J, Smith D S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994; 152 1837-1842
23 Morgan W R, Bergstralh E J, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 1993; 41 113-120
24 Partin A W, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993; 20 713-725
25 Wiegel T. The long-term results of radiotherapy in prostatic carcinoma recurrences after radical prostatectomy. Strahlenther Onkol. 1998; 174 643-644
26 Keyser D, Kupelian P A, Zippe C D, Levin H S, Klein E A. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?. Int J Radiat Oncol Biol Phys. 1997; 38 723-729
27 Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann H J, Molls M. Biochemical control after conformal, 3-dimensional radiotherapy of prostatic carcinoma. Strahlenther Onkol. 2002; 178 369-377
28 Noldus J, Stamey T A. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol. 1996; 155 232-237
29 Wolf J S, Cher M, Dall'era M, Presti J C, Hricak H, Carroll P R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995; 153 993-999
30 Bluestein D L, Bostwick D G, Bergstralh E J, Oesterling J E. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol. 1994; 151 1315-1320
31 Kattan M W, Eastham J A, Stapleton A M, Wheeler T M, Scardino P T. Apreoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90 766-771
32 Partin A W, Mangold L A, Lamm D M, Walsh P C, Epstein J I, Pearson J D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58 843-848
33 Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer. J Urol. 2001; 166 1715-1719
34 Miller J I, Ahmann F R, Drach G W, Emerson S S, Bottaccini M R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol. 1992; 147 956-961
35 Dinges S, Deger S, Koswig S, Boehmer D, Schnorr D, Wiegel T, Loening S A, Dietel M, Hinkelbein W, Budach V. High-dose rate interstitial with external beam irradiation for localized prostate cancer-results of a prospective trial. Radiother Oncol. 1998; 48 197-202
36 Lawton C A, Winter K, Byhardt R, Sause W T, Hanks G E, Russell A H, Rotman M, Porter A, McGowan D G, DelRowe J D, Pilepich M V. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1997; 38 931-939
37 D'Amico A V, Whittington R, Malkowicz S B, Cote K, Loffredo M, Schult D, Chen M H, Thomaszewski J E, Renshaw A A, Wein A, Richie J P. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically lcalized prostate carcinoma in the prostate specific antigen era. Cancer. 2002; 95 211-214
38 Zincke H, Utz D C, Taylor W F. Bilateral pelvic lymphadenectomy and radicalprostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression. J Urol. 1986; 135 1199-1205
39 Catalona W, Rickie J. et al . Comparison of digital rectal examination an serum PSA in the early detection of prostae cancer. Int J Cancer. 2002; 98 266-273
40 Zincke H, Bergstralh E J, Blute M L, Myers R P, Barrett D M, Lieber M M, Marti S K, Oesterling J E. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1 143 patients from a single institution. J Clin Oncol. 1994; 11 2254-2263
41 Breul J. Fehler bei der präoperativen Betsimmung des lokalen Tumorstadiums bei der radikalen Prostatektomie. In: Hartung P, Kropp W (Hrsg). Urologische Beckenchirurgie. Springer, Berlin, Heidelberg 1991
42 Partin A W, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993; 20 713-725
43 Wirth M, Tyrrell C, Wallace M, Delaere K P, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes C F, Borchers T M, Morris T, Stone A. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localizedor locally advanced prostate cancer significantly reduces the risk of disease progression. Urology. 2001; 58 146-151
44 Cadeddu J A, Partin A W, DeWeese T L, Walsh P C. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol. 1998; 159 173-177
45 Pisansky T M, Kozelsky T F, Myers R P, Hillman D W, Blute M L, Buskirk S J, Cheville J C, Ferrigni R G, Schild S E. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol. 2000; 163 845-850
46 Höcht S, Wiegel T, Schostak M, Hinkelbein W. Adjuvant and salvage radiotherapy after radical prostatectomy. Onkologie. 2002; 25 201-206
47 Wiegel T, Bressel M, Arps H, Hubener K H. Radiotherapy of local recurrence following radical prostatectomy. Strahlenther Onkol. 1992; 168 333-336
48 Takayama T K, Krieger J N, True L D, Lange P H. Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol. 1992; 148 1541-1542
49 Wirth M. Die Rolle des PSA in der Diagnostik des Prostatakarzinoms. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 105
50 Link P, Freiha F S, Stamey T A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol. 1991; 145 532-534
51 Wu J J, King S C, Montana G S, McKinstry C A, Anscher M S. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995; 32 317-323
52 Partin A W, Pearson J D, Landis P K, Carter H B, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology. 1994; 43 649-659
53 Denis L J, Carnelro de Moura J L, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology. 1993; 42 119-129
54 Spigelman S S, McNeal J E, Freiha F S, Stamey T A. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations. J Urol. 1986; 136 1228-1230
55 Devonec M, Fendler J P, Monsallier M, Mouriquand P, Maquet J H, Mestas J L, Dutrieux-Berger N, Perrin P. The significance of the prostatic hypoechoic area: results in 226 ultrasonically guided prostatic biopsies. J Urol. 1990; 143 316-319
56 Silverman J M, Krebs T L. MR imaging evaluation with a tranrectal surface coil of local recurrence of prostatic cancer in man who have undergone radical prostatectomy. AJR Am J Roentgenol. 1997; 168 379-385
57 Kurhanewicz J, Vigneron D B, Hricak H, Parivar F, Nelson S J, Shinohara K, Carroll P R. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging. Radiology. 1996; 200 489-496
58 Kramer S, Gorich J, Gottfried H W, Riska P, Aschoff A J, Rillinger N, Brambs H J, Sokiranski R. Sensitivity of computed tomography in detecting of local recurrence of prostatic carcinoma following radical prstatectomy. Br J Radiol. 1997; 70 995-999
59 Roscigno M, Scattoni V, Raber M, Consonni P, Montorsi F, Pasta A, Bertini R, Colombo R, Da Pozzo L, Freschi M, Rigatti P. Role of prostate fossa ultrasonography in the diagnosis of local recurrence after radical prostatectomy in case of PSA failure. Arch Ital Urol Androl. 2002; 74 304-308
60 Schiebler M L, Schnall M, Pollack H M, Lenkinski R E, Tomaszewski J E, Wein A J. Current role of MR imaging in the staging of Adenocarcimoma of the prostate. Radiology. 1993; 189 339-352
61 Jager G J, Barentsz J O, Oosterhof G O, Witjes J A, Ruijs S JH. Pelvic adenopathia in prostatic and bladder cancer: MR imaging with a three-dimensional T₁-weighted magnetization-prepared-rapid gradient-echo sequence. AJR. 1996; 176 1503-1507
62 Swindle P W, Kattan M W, Scardino P T. Markers and meaning of primary treatment failure. Urol Clin North Am. 2003; 30 377-401
63 Pound C R, Partin A W. What does prostate specific antigen recurrence mean?. Curr Urol Rep. 2002; 1 28-35
64 Scherr D, Swindle P W, Scardino P T. National comprehensive cancer network guidelines for the management of prostate cancer. Urology. 2003; 61 (Suppl 2 A) 14-24
65 Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, Hautmann R, Reske S N. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000; 27 1415-1419
66 Kotzerke J, Volkmer B G, Neumaier B, Gschwend J EA, Kleinschmidt K, Hautmann R E, Reske S N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl med Mol Imaging. 2002; 29 1380-1384
67 Kotzerke J, Volkmer B G, Glatting G, Hoff J, Gschwend J E, Messer P, Reske S N, Neumaier B. Intraindividual comparison of [¹¹C]acetate and [¹¹C]choline PET for Detection of metastases of prostate cancer. Nuklearmedizin. 2003; 42 25-30
68 Oyama N, Akino H, Kanamaru H, Suzuky J, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. ¹¹C-acetate PET imaging of prostate cancer. J Nucl Med. 2002; 43 181-186
69 Oyama N, Miller T R, Dehdashti F, Siegel B A, Fischer K C, Michalski J M, Kibel A S, Andriole G L, Picus J, Welch M J. ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2000; 44 549-555
70 Hara T, Kosaka N, Kondo T, Kishi H, Kobori O. Imaging of brain tumor, lung cancer; esophagus cancer, colon cancer, prostate cancer, and bladder cancer with [¹¹C]choline. J Nucl Med. 1997; 38 (Suppl) 250
71 Hautzel H, Müller-Mattheis V, Herzog H, Roden W, Coenen H H, Ackermann R, Müller-Gärtner H-W, Krause B J. Neue Perspektiven in der metabolischen Bildgebung beim Prostatakarzinom: Die ¹¹C-Azetat Positronen Emissions-Tomographie. Urologe A. 2002; 41 569-576
72 Frazier H A, Robertson J E, Humphrey P A, Paulson D F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol. 1993; 149 516-518
73 Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei D V, De Corbelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F. Value of [¹¹C]choline positron emission tomography for restaging prostate cancer: a comparison with [¹⁸F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003; 169 1337-1340
74 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. Preoperative staging of pelvic lymph nodes in Prostate Cancer by ¹¹C-Cholin PET. J Nucl Med. 2003; 44 331-335
75 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. Visualisation of prostate cancer with ¹¹C-choline positron emission tomography. Eur Urol. 2002; 42 18-23
76 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. ¹¹C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003; 44 32-38
77 Dhingsa R, Qayyum A, Coakley F V, Lu Y, Jones K D, Swanson M G, Carroll P R, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiolog. 2004; 230 215-220

Dr. Norbert M. Blumstein

Abteilung Nuklearmedizin, Universitätsklinikum Ulm

Robert Koch-Str. 8

89081 Ulm

Telefon: 00 49/(0)7 31/50 02 45 00

Fax: 00 49/(0)7 31/50 02 45 03

eMail: norbert-manfred.blumstein@medizin.uni-ulm.de